{"filing":{"accession_number":"0001171843-26-006028","cik":"0001828253","ticker":"EVAX","company_name":"Evaxion A/S","form":"6-K","filing_date":"2026-09-14","report_date":"2026-09-14","primary_document":"f6k_091426.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1828253/000117184326006028/f6k_091426.htm"},"events":[{"id":33147,"run_id":30472,"accession_number":"0001171843-26-006028","anchor_item_number":"EX-99.1","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"summary":"Evaxion announces expansion of its AI-Immunology™ platform into a new therapeutic area (autoimmune diseases) with two novel treatment concepts under experimental testing. This represents a material strategic expansion of the company's therapeutic focus and pipeline, with data to be presented at a major industry conference (PEGS Europe, November 18, 2026). While not a discrete M\u0026A, financing, or personnel event, this disclosure of a significant new therapeutic direction and experimental validation milestone would affect a reasonable investor's assessment of the company's strategic positioning and pipeline diversification.","company_name":"Evaxion A/S","ticker":"EVAX","filing_date":"2026-09-14","form":"6-K","submitted_at":null,"items":[{"id":36516,"accession_number":"0001171843-26-006028","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Evaxion announces expansion of its AI-Immunology™ platform into a new therapeutic area (autoimmune diseases) with two novel treatment concepts under experimental testing. This represents a material strategic expansion of the company's therapeutic focus and pipeline, with data to be presented at a major industry conference (PEGS Europe, November 18, 2026). While not a discrete M\u0026A, financing, or personnel event, this disclosure of a significant new therapeutic direction and experimental validation milestone would affect a reasonable investor's assessment of the company's strategic positioning and pipeline diversification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T12:06:40.761534+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36516,"accession_number":"0001171843-26-006028","item_number":"EX-99.1","item_title":"exh_991.htm","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Evaxion announces expansion of its AI-Immunology™ platform into a new therapeutic area (autoimmune diseases) with two novel treatment concepts under experimental testing. This represents a material strategic expansion of the company's therapeutic focus and pipeline, with data to be presented at a major industry conference (PEGS Europe, November 18, 2026). While not a discrete M\u0026A, financing, or personnel event, this disclosure of a significant new therapeutic direction and experimental validation milestone would affect a reasonable investor's assessment of the company's strategic positioning and pipeline diversification.","classifier_version":"claude-haiku-4-5-20251001+prompt-6be895f9","taxonomy_version":"v1.3","classified_at":"2026-09-14T12:06:40.761534+00:00","company_name":"Evaxion A/S","ticker":"EVAX","filing_date":"2026-09-14"}]}